Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer.
Aghdam N, Pepin AN, Creswell M, Hsieh K, Smith C, Drescher N, Danner M, Ayoob M, Yung T, Lei S, Kumar D, Collins BT, Lischalk JW, Krishnan P, Suy S, Lynch J, Bandi G, Hankins RA, Collins SP. Aghdam N, et al. Among authors: kumar d. Front Oncol. 2020 Oct 29;10:551491. doi: 10.3389/fonc.2020.551491. eCollection 2020. Front Oncol. 2020. PMID: 33251131 Free PMC article.
Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy.
Carrasquilla M, Creswell ML, Pepin AN, Wang E, Forsthoefel M, McGunigal M, Bullock E, Lei S, Collins BT, Lischalk JW, Esposito G, Aghdam N, Kumar D, Suy S, Leger P, Hankins RA, Dawson NA, Collins SP. Carrasquilla M, et al. Among authors: kumar d. Front Oncol. 2021 Jan 18;10:606260. doi: 10.3389/fonc.2020.606260. eCollection 2020. Front Oncol. 2021. PMID: 33537236 Free PMC article. Review.
Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer.
Aghdam N, Carrasquilla M, Wang E, Pepin AN, Danner M, Ayoob M, Yung T, Collins BT, Kumar D, Suy S, Collins SP, Lischalk JW. Aghdam N, et al. Among authors: kumar d. Front Oncol. 2021 Feb 25;10:616286. doi: 10.3389/fonc.2020.616286. eCollection 2020. Front Oncol. 2021. PMID: 33718117 Free PMC article.
Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer.
Sholklapper TN, Creswell ML, Payne AT, Markel M, Pepin A, Carrasquilla M, Zwart A, Danner M, Ayoob M, Yung T, Collins B, Kumar D, Aghdam N, Suy S, Hankins RA, Kowalczyk K, Collins SP. Sholklapper TN, et al. Among authors: kumar d. Front Oncol. 2022 Mar 25;12:852844. doi: 10.3389/fonc.2022.852844. eCollection 2022. Front Oncol. 2022. PMID: 35402242 Free PMC article.
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Gallagher L, Xiao J, Hsueh J, Shah S, Danner M, Zwart A, Ayoob M, Yung T, Simpson T, Fallick M, Kumar D, Leger P, Dawson NA, Suy S, Collins SP. Gallagher L, et al. Among authors: kumar d. Front Oncol. 2023 Oct 17;13:1289249. doi: 10.3389/fonc.2023.1289249. eCollection 2023. Front Oncol. 2023. PMID: 37916156 Free PMC article.
7,302 results